ZA200403452B - Coffee plant with reduced alpha-D-galactosidase activity - Google Patents

Coffee plant with reduced alpha-D-galactosidase activity Download PDF

Info

Publication number: ZA200403452B
Authority: ZA; South Africa
Prior art keywords: coffee; galactosidase; plant; sequence; mrna
Prior art date: 2001-10-10

Application number

ZA200403452A

Other languages

English (en)

Inventor

Pierre Marraccini

Alain Deshayes

John Rogers

Original Assignee

Nestle Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-10

Filing date

2004-05-06

Publication date

2006-07-26

2004-05-06 Application filed by Nestle Sa filed Critical Nestle Sa

2006-07-26 Publication of ZA200403452B publication Critical patent/ZA200403452B/en

Links

230000000694 effects Effects 0.000 title claims abstract description 29
240000007154 Coffea arabica Species 0.000 title claims description 51
108010030291 alpha-Galactosidase Proteins 0.000 title abstract description 4
102000005840 alpha-Galactosidase Human genes 0.000 title abstract 3
241000196324 Embryophyta Species 0.000 claims abstract description 27
241000533293 Sesbania emerus Species 0.000 claims abstract description 9
229920000926 Galactomannan Polymers 0.000 claims abstract description 8
235000013353 coffee beverage Nutrition 0.000 claims description 28
230000000692 anti-sense effect Effects 0.000 claims description 18
108020004999 messenger RNA Proteins 0.000 claims description 17
108090000623 proteins and genes Proteins 0.000 claims description 17
229930182830 galactose Natural products 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
229920000057 Mannan Polymers 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 7
235000021539 instant coffee Nutrition 0.000 claims description 6
108020004707 nucleic acids Proteins 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
229920002477 rna polymer Polymers 0.000 claims description 4
244000046052 Phaseolus vulgaris Species 0.000 claims description 3
235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 2
238000012986 modification Methods 0.000 abstract description 2
230000004048 modification Effects 0.000 abstract description 2
239000013598 vector Substances 0.000 description 32
239000002299 complementary DNA Substances 0.000 description 19
210000004027 cell Anatomy 0.000 description 12
230000000875 corresponding effect Effects 0.000 description 12
210000002257 embryonic structure Anatomy 0.000 description 11
230000014509 gene expression Effects 0.000 description 10
239000002773 nucleotide Substances 0.000 description 10
125000003729 nucleotide group Chemical group 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
108010093031 Galactosidases Proteins 0.000 description 9
230000035800 maturation Effects 0.000 description 9
239000000047 product Substances 0.000 description 9
230000000392 somatic effect Effects 0.000 description 9
230000009466 transformation Effects 0.000 description 9
102000002464 Galactosidases Human genes 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
241000589155 Agrobacterium tumefaciens Species 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
108020005544 Antisense RNA Proteins 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
230000003321 amplification Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000006870 ms-medium Substances 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000007993 MOPS buffer Substances 0.000 description 3
108010002747 Pfu DNA polymerase Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000000137 annealing Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000031787 nutrient reservoir activity Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
101100352418 Caenorhabditis elegans plp-1 gene Proteins 0.000 description 2
235000007460 Coffea arabica Nutrition 0.000 description 2
244000016593 Coffea robusta Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
-1 galactomannan polysaccharides Chemical class 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
241000769888 Canephora <angiosperm> Species 0.000 description 1
239000005496 Chlorsulfuron Substances 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000723377 Coffea Species 0.000 description 1
235000002187 Coffea robusta Nutrition 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
240000002769 Morchella esculenta Species 0.000 description 1
235000002779 Morchella esculenta Nutrition 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010016634 Seed Storage Proteins Proteins 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000021759 endosperm development Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000035784 germination Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000005213 imbibition Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
208000035851 morphological anomaly Diseases 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
239000012882 rooting medium Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Nutrition Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Tea And Coffee (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

ZA200403452A 2001-10-10 2004-05-06 Coffee plant with reduced alpha-D-galactosidase activity ZA200403452B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01124160		2001-10-10

Publications (1)

Publication Number	Publication Date
ZA200403452B true ZA200403452B (en)	2006-07-26

Family

ID=8178911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200403452A ZA200403452B (en)	2001-10-10	2004-05-06	Coffee plant with reduced alpha-D-galactosidase activity

Country Status (16)

Country	Link
US (1)	US7238858B2 (de)
EP (1)	EP1436402B1 (de)
JP (1)	JP4276945B2 (de)
CN (1)	CN1635895A (de)
AT (1)	ATE318319T1 (de)
AU (1)	AU2002333434B2 (de)
BR (1)	BR0213180A (de)
CA (1)	CA2457821A1 (de)
CO (1)	CO5580845A2 (de)
DE (1)	DE60209380T2 (de)
ES (1)	ES2258173T3 (de)
MY (1)	MY129821A (de)
OA (1)	OA12667A (de)
RU (1)	RU2303349C2 (de)
WO (1)	WO2003032713A2 (de)
ZA (1)	ZA200403452B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007087113A2 (en)	2005-12-28	2007-08-02	The Scripps Research Institute	Natural antisense and non-coding rna transcripts as drug targets
ES2727549T3 (es)	2008-10-03	2019-10-17	Curna Inc	Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
JP5923306B2 (ja)	2008-12-04	2016-05-24	クルナ・インコーポレーテッド	腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療
ES2600781T3 (es)	2008-12-04	2017-02-10	Curna, Inc.	Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
ES2627763T3 (es)	2009-03-17	2017-07-31	Curna, Inc.	Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP6250930B2 (ja)	2009-05-06	2017-12-20	クルナ・インコーポレーテッド	トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
EP2427554B1 (de)	2009-05-08	2016-11-16	CuRNA, Inc.	Behandlung von dystrophin-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen die dmd-familie
CN102575251B (zh)	2009-05-18	2018-12-04	库尔纳公司	通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
JP2012527248A (ja)	2009-05-22	2012-11-08	クルナ・インコーポレーテッド	転写因子ｅ３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるｔｆｅ３およびインスリン受容体基質２（ｉｒｓ２）関連疾患の処置
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CA2765509C (en)	2009-06-16	2021-08-17	Joseph Collard	Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
KR101807323B1 (ko)	2009-06-24	2017-12-08	큐알엔에이, 인크.	Ｔｎｆｒ2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(ｔｎｆｒ2) 관련된 질환의 치료
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en)	2009-07-24	2018-06-19	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP2462229B1 (de)	2009-08-05	2016-05-11	CuRNA, Inc.	Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
CN102625841A (zh)	2009-08-11	2012-08-01	欧科库尔纳有限责任公司	通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
US8791087B2 (en)	2009-08-21	2014-07-29	Curna, Inc.	Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
CA2771172C (en)	2009-08-25	2021-11-30	Opko Curna, Llc	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
JP6175236B2 (ja)	2009-09-25	2017-08-09	カッパーアールエヌエー，インコーポレイテッド	フィラグリン（ｆｌｇ）の発現および活性の調整によるｆｌｇ関連疾患の処置
KR101823702B1 (ko)	2009-12-16	2018-01-30	큐알엔에이, 인크.	막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
WO2011079212A2 (en) *	2009-12-24	2011-06-30	LifeSpan Extension, LLC	Methods and compositions for identifying, producing and using plant-derived products modulating cell function and aging
WO2011090740A2 (en)	2009-12-29	2011-07-28	Opko Curna, Llc	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
KR101853511B1 (ko)	2009-12-31	2018-06-20	큐알엔에이, 인크.	인슐린 수용체 기질 2 및 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의한 ｉｒｓ2 관련된 질환의 치료
KR101878501B1 (ko)	2010-01-04	2018-08-07	큐알엔에이, 인크.	인터페론 조절 인자 8 (ｉｒｆ8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (ｉｒｆ8) 관련된 질환의 치료
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
CA2786535C (en)	2010-01-11	2019-03-26	Curna, Inc.	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
JP5981850B2 (ja)	2010-01-25	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
JP5976548B2 (ja)	2010-02-22	2016-08-23	カッパーアールエヌエー，インコーポレイテッド	Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
US8980856B2 (en)	2010-04-02	2015-03-17	Curna, Inc.	Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
WO2011127337A2 (en)	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CA2798218A1 (en)	2010-05-03	2011-11-10	Curna, Inc.	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP2576783B1 (de)	2010-05-26	2017-11-29	CuRNA, Inc.	Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
JP5917497B2 (ja)	2010-05-26	2016-05-18	カッパーアールエヌエー，インコーポレイテッド	メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療
CN103025873B (zh)	2010-06-23	2018-05-08	库尔纳公司	通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
RU2624048C2 (ru)	2010-10-06	2017-06-30	Курна, Инк.	Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
WO2012054723A2 (en)	2010-10-22	2012-04-26	Opko Curna Llc	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
KR102010598B1 (ko)	2010-11-23	2019-08-13	큐알엔에이, 인크.	Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
EA029151B1 (ru)	2011-09-06	2018-02-28	Курна, Инк.	ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
WO2013138374A2 (en)	2012-03-15	2013-09-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102643800B (zh) *	2012-04-25	2014-02-05	中国科学院植物研究所	一种提取植物dna的方法及其专用试剂盒
GB201708665D0 (en) *	2017-05-31	2017-07-12	Tropic Biosciences Uk Ltd	Compositions and methods for increasing extractability of solids from coffee beans

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6329191B1 (en) *	1993-08-30	2001-12-11	Hawaii Biotechnology Group, Inc.	DNA encoding recombinant coffee bean alpha-galactosidase
EP1138771A1 (de) *	2000-03-30	2001-10-04	Societe Des Produits Nestle S.A.	Endo-Mannanase aus Kaffee

2002
- 2002-08-15 DE DE60209380T patent/DE60209380T2/de not_active Expired - Lifetime
- 2002-08-15 CN CNA028200861A patent/CN1635895A/zh active Pending
- 2002-08-15 AU AU2002333434A patent/AU2002333434B2/en not_active Ceased
- 2002-08-15 RU RU2004114230/13A patent/RU2303349C2/ru not_active IP Right Cessation
- 2002-08-15 EP EP02801285A patent/EP1436402B1/de not_active Expired - Lifetime
- 2002-08-15 BR BR0213180-3A patent/BR0213180A/pt not_active IP Right Cessation
- 2002-08-15 ES ES02801285T patent/ES2258173T3/es not_active Expired - Lifetime
- 2002-08-15 WO PCT/EP2002/009148 patent/WO2003032713A2/en active IP Right Grant
- 2002-08-15 AT AT02801285T patent/ATE318319T1/de not_active IP Right Cessation
- 2002-08-15 JP JP2003535528A patent/JP4276945B2/ja not_active Expired - Fee Related
- 2002-08-15 CA CA002457821A patent/CA2457821A1/en not_active Abandoned
- 2002-08-15 OA OA1200400102A patent/OA12667A/en unknown
- 2002-08-26 MY MYPI20023142A patent/MY129821A/en unknown
2004
- 2004-03-19 US US10/804,096 patent/US7238858B2/en not_active Expired - Lifetime
- 2004-04-05 CO CO04032188A patent/CO5580845A2/es not_active Application Discontinuation
- 2004-05-06 ZA ZA200403452A patent/ZA200403452B/en unknown

Also Published As

Publication number	Publication date
DE60209380T2 (de)	2006-10-19
RU2303349C2 (ru)	2007-07-27
US7238858B2 (en)	2007-07-03
JP2005505290A (ja)	2005-02-24
WO2003032713A2 (en)	2003-04-24
CA2457821A1 (en)	2003-04-24
EP1436402A2 (de)	2004-07-14
EP1436402B1 (de)	2006-02-22
AU2002333434B2 (en)	2007-12-13
BR0213180A (pt)	2004-09-14
US20040199943A1 (en)	2004-10-07
OA12667A (en)	2006-06-19
RU2004114230A (ru)	2005-04-20
WO2003032713A3 (en)	2003-11-13
ATE318319T1 (de)	2006-03-15
CO5580845A2 (es)	2005-11-30
JP4276945B2 (ja)	2009-06-10
CN1635895A (zh)	2005-07-06
ES2258173T3 (es)	2006-08-16
MY129821A (en)	2007-05-31
DE60209380D1 (de)	2006-04-27

Publication	Publication Date	Title
US7238858B2 (en)	2007-07-03	Coffee plant with reduced α-D-galactosidase activity
AU2002333434A1 (en)	2003-07-03	Coffee plant with reduced alpha-D-galactosidase activity
US6235482B1 (en)	2001-05-22	Strawberry promoters and genes
EP0316441B1 (de)	2001-12-05	Obstspezifische transcriptionsfaktoren
CA2775650A1 (en)	2003-08-28	Compositions and methods for modifying a plant trait by p-dna
JP2000503848A (ja)	2000-04-04	植物におけるトランスジーンの制御された発現のための植物組織／期特異的プロモーター
Hardegger et al.	1998	Transformation and regeneration of carrot (Daucus carota L.)
EP1256629A1 (de)	2002-11-13	Blattspezifischer Promoter aus Kaffee
US6127179A (en)	2000-10-03	Gene promoter for tomato fruit
EP1081223B1 (de)	2006-05-10	In antheren und pollen exprimierte promotorsequenzen
Rossi et al.	1998	Analysis of an abscisic acid (ABA)-responsive gene promoter belonging to the Asr gene family from tomato in homologous and heterologous systems
EP1149915A1 (de)	2001-10-31	Modifikation der Genexpression in transgenen Pflanzen
Okada et al.	2003	Construction of gene expression system in hop (Humulus lupulus) lupulin gland using valerophenone synthase promoter
US5569831A (en)	1996-10-29	Transgenic tomato plants with altered polygalacturonase isoforms
HU217421B (hu)	2000-01-28	Eljárás proteinszintézis-inhibitort kódoló DNS és a kódolt protein előállítására, valamint eljárás ezek alkalmazására patogének leküzdésében
Nap et al.	1992	Analysis of the region in between two closely linked patatin genes: class II promoter activity in tuber, root and leaf
KR20050018626A (ko)	2005-02-23	감소된 α-Ｄ-갈락토시다아제 활성을 갖는 커피 식물
CA2538484A1 (en)	2005-03-24	Novel endosperm-specific plant promoter for cultivated plants
US6812381B2 (en)	2004-11-02	DNA fragment having promoter function
CN116640200A (zh)	2023-08-25	调控MfERF086基因在紫花苜蓿生长发育和/或耐冷性中的应用
RU2145636C1 (ru)	2000-02-20	Способ индуцирования образования цветков у растений
CN116640201A (zh)	2023-08-25	调控MfERF026基因在紫花苜蓿生长发育和耐胁迫中的应用